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Tuberculosis (TB) is still a prevalent disease, one third
of the population is infected by mycobacterium tubercu-
losis (MT).Treatment with anti TNF therapies appears
to increase the risk for developing TB
Aim
to study the occurrence of latent TB (LTB) or tubercu-
losis disease (TBD) in children with JIA under anti TNF
therapy.
Methods
Clinical records from pts with JIA ( ILAR’01) under
anti-TNF therapy were reviewed, focusing on TB
screening prior to biologicals , PPD conversion or TBD
diagnosiss.LTB was considered as a PPD (TST) positive
(≥ 5 mm), in the abscense of radiological manifestations
of TB.
Results
105 JIA pts received one or more anti TNF drugs during
the observation. Four of them developed LTB and 3
others TBD.
No extrapulmonar TB or miliary forms were observed.
All patients were PPD negative prior to biological agents
Conclusions
No significative difference was found between specific
anti TNF and the occurrence of LTB or TBD. In 4 pts,
the infectious event occurred after 2 ys of exposure and
in two earlier as described in the literature. This data
highlights the importance of TB surveillance prior to
and during anti-TNF therapy.
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Table
Gender/ age( ys) Dx PPD (mm)* TBDisease antiTNF Time under 1st Biologic TB tx 2nd Biological Tx
Pt 1 M / 18 pJIA 18 no ETN 24 m INH No
Pt 2 F/ 20 oJIA 12 no ADA 24 m INH No
Pt 3 F / 7 pJIA 6 no ETN 11 m INH INF
Pt 4 M / 13 sJIA 13 no IFX 1 m INH No
Pt 5 F / 14 pJIA 10 Pulmonar involvement IFX 6 m 4 drugs ETN
Pt 6 F / 17 pJIA 13 Pulmonar involvement IFX 24 m 4 drugs No
Pt 7 F / 12 pJIA 13 Pulmonar involvement ETN 30 m 4 drugs ETN
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